Prime Medicine (PRME) said late Wednesday it priced a public offering of 38 million common shares at $3.30 each for about $125.4 million in expected gross proceeds.
Underwriters have a 30-day overallotment option to buy up to 5.7 million additional shares. The company said the underwriters will not receive discounts or commissions for 1.8 million shares sold to the Cystic Fibrosis Foundation.
The offering is expected to close Friday.
Prime Medicine shares were down 8.4% in recent premarket activity Thursday.